What is it about?
There is a strong ramping up of trials of cell-based therapies for COVID-19 respiratory disease. These are mostly MSC-based but also encompass exosomes and other cell types. As such, we review all the current available pre-clinical evidence (all with influenza models; none available with coronavirus models), proposed mechanisms of MSC actions in respiratory virus infections, recently published clinical investigations in China, and then the scope of proposed clinical investigation and suggestions for cautious and effective strategies are discussed
Featured Image
Why is it important?
its critically important to understand the underlying rationale and available evidence. This in particular as there is no rhyme or reason for the proposed trials: different cell sources, doses, dosing strategies, and in particular no consensus on which patients are most appropriate to target.
Perspectives
It is imperative to better comprehend the rationale and underlying data which both supports and refutes effectiveness of MSCs in respiratory virus infections, and to define the targeted patient population and best strategies for cell therapy approaches.
MAroun Khoury
Universidad de Los Andes
Read the Original
This page is a summary of: Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19, European Respiratory Journal, April 2020, European Respiratory Society (ERS),
DOI: 10.1183/13993003.00858-2020.
You can read the full text:
Contributors
The following have contributed to this page
